Hydrochlorothiazide and Prevention of Kidney-Stone RecurrenceNasser A. Dhayat, Daniel G. Fuster, Irene Koneth et al.|New England Journal of Medicine|2023Cited by 128
Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trialSimeon Schietzel, Daniel G. Fuster, Lia Bally et al.|BMJ Open|2022Cited by 31
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trialManuel Anderegg, Daniel G. Fuster, Simeon Schietzel et al.|Nature Medicine|2025Cited by 25
Hydrochlorothiazide and Bone Mineral Density in Patients with Kidney StonesAndreas Christe, Daniel G. Fuster, Elias Primetis et al.|Clinical Journal of the American Society of Nephrology|2025Cited by 1
A Randomized, Double-Blind, Placebo-Controlled Trial Assessing Efficacy of Standard and Low-Dose Hydrochlorothiazide Treatment for Prevention of Recurrent Calcareous Nephrolithiasis (NOSTONE Trial)Nasser A. Dhayat, Olivier Bonny, Beat Roth et al.|Journal of the American Society of Nephrology|2020Cited by 0